Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Incorporating Immune Checkpoint Inhibitors Into Practice for Advanced Urothelial Cancer: Expert Perspectives From the Netherlands and the United Kingdom

In this episode, listen to Thomas Powles, MBBS, MRCP, MD, and Michiel van der Heijden, MD, PhD, discuss key data on immune checkpoint inhibitors for urothelial carcinoma informing their clinical practice in the United Kingdom and the Netherlands.
person default
Thomas Powles, MBBS, MRCP, MD
Michiel van der Heijden, MD, PhD
Released: November 20, 2020

In this episode, Thomas Powles, MBBS, MRCP, MD, and Michiel van der Heijden, MD, PhD, discuss key data on immune checkpoint inhibitors for urothelial carcinoma informing their clinical practice in the United Kingdom and the Netherlands. Topics include:

  • Data from registrational trials in the European Union for pembrolizumab and atezolizumab in the first-line/second-line settings
  • Utility of PD-L1 and tumor mutational burden as biomarkers for immune checkpoint inhibitor–based therapy
  • Results from the JAVELIN trial on avelumab maintenance after chemotherapy
  • When to consider first-line treatment with immune checkpoint inhibitor–based therapy vs chemotherapy

Presenters:

Thomas Powles, MBBS, MRCP, MD
Deputy Centre Lead
Centre for Experimental Cancer Medicine
Barts Cancer Institute
Queen Mary University of London
Professor of Urology Cancer
Director of Barts Cancer Centre
Department of Cancer
St Bartholomew's Hospital (Barts Health NHS Trust)
London, United Kingdom

Michiel van der Heijden, MD, PhD
Medical Oncologist and Research Group Leader
Department of Medical Oncology and Molecular Carcinogenesis
Stichting Het Nederlands Kanker Instituut – Antoni van Leeuwenhoek Ziekenhuis
Medical Oncologist 
Antoni van Leeuwenhoek Ziekenhuis/Netherlands Cancer Institute
Amsterdam, the Netherlands

Acknowledgements

Supported by an educational grant from
Pfizer, Inc. and EMD Serono

Related Content

First results from PEACE-1 trial of abiraterone with or without local radiotherapy plus SOC in metastatic CSPC, from ASCO 2021 as reported by Clinical Care Options (CCO)

Released: June 17, 2021

Downloadable slideset from Eric Jonasch, MD on managing irAEs in patients with advanced RCC, from Clinical Care Options (CCO).

Eric Jonasch, MD Released: June 16, 2021

Downloadable slideset from Dr Elizabeth R. Plimack on first-line treatment options for patients with RCC, from Clinical Care Options (CCO)

Elizabeth R. Plimack, MD, MS Released: June 16, 2021

Downloadable slideset from Neeraj Agarwal, MD on treatment options for salvage therapy in advanced RCC, from Clinical Care Options (CCO)

Neeraj Agarwal, MD Released: June 16, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue